Pay in 4 interest-free payments of $5.94 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
In a phase 2 trial, once-monthly dosing produced significant weight loss at 52 weeks: 12.3% to 16.2% in patients with obesity without diabetes ( vs 2.5% with placebo), and 8.4% to -12.3% in those with obesity and type 2 diabetes ( vs 1.7% with placebo)
Bilic I et al
When someone says, I'm on GLP-1 , they are really talking about a class of drugs, not a specific treatment
Altered cardiac markers included reactive cTnI, significantly increased total CK, CK-MB, relative CK-MB index, and LDH
Regular liver function tests may be recommended by healthcare providers to monitor liver health during treatment
US$ 22.95
US$ 21.71
US$ 25.12
US$ 27.24
/product/02/3175523/1.jpg?6062)
US$ 24.94
